Pharma In Brief

05 January 2004 00:00  [Source: ICB Americas]

HYDROXYETHYL CELLULOSE Dow Chemical Company is increasing the price of Cellosize Hydroxy-ethyl Cellulose products sold to customers in Asia, Pacific and Middle East locations by $0.40 per kilogram, effective January 1, 2004.

MENACTRA Aventis Pasteur, the vaccines unit of Aventis, has filed a biologics licensing application with the FDA for Menactra vaccine, the first quadrivalent conjugate candidate for the prevention of meningococcal meningitis, the most deadly of the three main types of meningitis.

ROFLUMILAST Altana AG, in conjunction with its development partner Pfizer Inc., will file for European approval of its respiratory drug Daxas (roflumilast) in February 2004. The filing was originally expected for the last quarter of 2003. Altana is expected to seek FDA approval for the phosphodiesterase-4 inhibitor for the treatment of chronic obstructive pulmonary disease and asthma in 2004. West LB AG expects the drug will bring in $1 billion in sales by 2010.

TERBINAFINE Teva Pharma-ceutical Industries Ltd. has received tentative FDA approval for its abbreviated new drug application for terbinafine hydrochloride tablets, 250 mg, the generic equivalent of Novartis's Lamisil tablets. The company expects final approval upon expiry of patent protection for Lamisil in December 2006. The branded product has annual sales of approximately $541 million.

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly